Security key
03836J102
Aprea Therapeutics, Inc. - Common Stock, par value $0.001 per share (APRE)
CUSIP: 03836J102
Q4 2022 13F Holders as of 31 Dec 2022
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 1,587,074
- Total 13F value
- $520,280
- Share change
- -44,778
- Put/Call ratio
- 2.5%
- SEC-reported price per share
- $0.33
- Number of holders
- 23
- Value change
- -$37,678
- Number of buys
- 12
- Number of sells
- 10
- Shares outstanding
- 228,836,687
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2022
Institutions
23
Top holders
10
APRE full security history
Ownership snapshot
Full 13F holder table
Aprea Therapeutics, Inc. SEC filings
Aprea Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of APRE - Aprea Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Christian S. Schade
Disclosed value leader
Christian S. Schade
Comparable rows
0/15
Latest evidence
30 Sep 2022
3/4/5
13F
Highest disclosed value: $976,345
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Christian S. Schade has the largest disclosed position value at $976.3K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Christian S. Schade's linked filing trail.
Disclosed position value
Top 5
Christian S. Schade
$976.3K
Scott M. Coiante
$534K
Eyal C. Attar
$211.3K
MORGAN STANLEY
$202K
VANGUARD GROUP INC
$201K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Christian S. Schade |
3/4/5
Director
|
—
mixed-class rows
|
$976,345
312,846 shares
mixed-class rows
|
— | 28 Jul 2022 |
| Scott M. Coiante |
3/4/5
SVP, Chief Financial Officer
|
—
mixed-class rows
|
$533,970
234,265 shares
mixed-class rows
|
— | 28 Jul 2022 |
| Eyal C. Attar |
3/4/5
SVP, Chief Medical Officer, Director
|
—
denominator unverified
|
$211,254
57,392 shares
|
— | 03 Jun 2022 |
| MORGAN STANLEY |
13F
Company
|
—
denominator unverified
|
$202,000
311,591 shares
|
— | 30 Sep 2022 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$201,000
309,598 shares
|
— | 30 Sep 2022 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
denominator unverified
|
$184,000
282,541 shares
|
— | 30 Sep 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
23
Shares
1,587,074
Rows available
23
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2022 vs Q3 2022 Across Filers
Q3 2022 holders
23
Q4 2022 holders
23
Holder diff
0
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 value | Q4 2022 value | Value change | Value Chg % |
|---|